GENE ONLINE|News &
Opinion
Blog

2021-11-27| Trials & Approvals

Brukinsa Receives EU Approval for the Treatment of Rare Lymphoma

by Rajaneesh K. Gopinath
Share To
Just months after receiving FDA approval, BeiGene's Brukinsa (zanubrutinib) has garnered authorization from the European Commission for treating Waldenström’s macroglobulinemia (WM), a rare type of lymphoma.

On November 23rd, BeiGene announced that the EC has approved Brukinsa for patients with WM who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy The approval follows a positive CHMP opinion granted last September after the drug registered encouraging Phase 3 results in the ASPEN trial.

Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) that originally bagged FDA approval for treating Mantle Cell Lymphoma in 2019. In September 2021, it received the agency's nod for a second indication, this time to treat WM. With the latest approval, Brkinsa is now okayed for WM treatment in China, Canada, the US, and 27 European Union member states, plus Iceland and Norway.



GO Prime with only $1.49 now

LATEST
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
FDA Allows Sales of Over-the-Counter Hearing Aids After Five Years of Consideration
2022-08-17
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK’s Second Billion Dollar Acquisition Outprices their First of 2022
2022-08-16
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
Antibody Treatment for Multiple Varieties of CoronaVirus
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-14
Bio Asia Pacific 2022
Tailand
2022-09-14
The Future of Health
Online
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!